The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics
Michal Schnaider Beeri, Ramit Ravona-Springer, Erin Moshier, James Schmeidler, James Godbold, Tomas Karpati, Derek Leroith, Keren Koifman, Efrat Kravitz, Rachel Price, Hadas Hoffman, Jeremy M Silverman, Anthony Heymann, Michal Schnaider Beeri, Ramit Ravona-Springer, Erin Moshier, James Schmeidler, James Godbold, Tomas Karpati, Derek Leroith, Keren Koifman, Efrat Kravitz, Rachel Price, Hadas Hoffman, Jeremy M Silverman, Anthony Heymann
Abstract
Background: Type 2 diabetes (T2D) is associated with increased risk of dementia. The prospective longitudinal Israel Diabetes and Cognitive Decline study aims at identifying T2D-related characteristics associated with cognitive decline.
Methods: Subjects are population-based T2D 65+, initially cognitively intact. Medical conditions, blood examinations, and medication use data are since 1998; cognitive, functional, demographic, psychiatric, DNA, and inflammatory marker study assessments were conducted every 18 months. Because the duration of T2D reflects its chronicity and implications, we compared short (0-4.99 years), moderate (5-9.99), and long (10+) duration for the first 897 subjects.
Results: The long duration group used more T2D medications, had higher glucose, lower glomerular filtration rate, slower walking speed, and poorer cognitive functioning. Duration was not associated with most medical, blood, urine, and vital characteristics.
Conclusions: Tracking cognition, with face-to-face evaluations, exploiting 15 years of historical detailed computerized, easily accessible, and validated T2D-related characteristics may provide novel insights into T2D-related dementia.
Keywords: Cognitive decline; Cognitively normal; Dementia; Elderly; Risk factors; Study design; Type 2 diabetes.
Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Figures
Source: PubMed